BIO Web Conf.
Volume 14, 2019The 12th International Conference on the Health Effects of Incorporated Radionuclides (HEIR 2018)
|Number of page(s)||1|
|Section||Epidemiology: Oral presentations|
|Published online||07 May 2019|
Lung, liver and bone cancer lifetime risk after intake of 239Pu
Southern Ural Biophysics Institute, Ozyorsk, Russian Federation
Workers involved in processing of 239Pu are subject to two major intake pathways of the nuclide: inhalation and wounds. While the inhalation intake limit is based in understanding of Pu biokinetics and lung clearance, the intake limits for intake via wounds do not exist.
Three organs in the human body are subject to greatest exposures from incorporated Pu: lung, liver and bone after inhalation intake and liver bone after intake through wounded skin.
Earlier we have calculated excess risk of lung, liver and bone cancer related to inhalation intake of 239Pu in Mayak Worker Cohort. In our current report we use these models to calculate lifetime risk of lung, liver and bone cancer after 239Pu intake via inhalation and wounded skin.
In order to do this, we calculated equivalent doses resulting from 239Pu incorporation in lung, liver and bone according to several scenarios including (among others) chronic inhalation intake at the level of annual limit of intake (ALI). We used Lifetime Excess Risk (LER) and Risk of Exposure Induced Death (REID) and their annual increments as characteristics of excess lifetime detriment caused by incorporated 239Pu.
For the scenario of chronic intake at the ALI level we demonstrate that at age 70 the annual lifetime risk increment of lung cancer is by a factor of 4 higher than that assumed by regulatory bodies as acceptable (0.001 per year).
We discuss the reasons for that and possible ways of avoiding extra carcinogenic risk in workers who contact to 239Pu or other transuranium nuclides with long biological half-life.
© The Authors, published by EDP Sciences, 2019
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.